Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01857193
Title Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Recruitment Completed
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

progesterone-receptor positive breast cancer

estrogen-receptor positive breast cancer

Therapies

Everolimus + Exemestane + Ribociclib

Exemestane + Ribociclib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.